Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a structural cardiac condition with a significant ventricular arrhythmia burden. The first-line treatment strategy targets both arrhythmia reduction and factors that can accelerate disease progression.

First-line management centres on beta-blocker therapy — carefully titrated upward — combined with a specific lifestyle modification. The complete regimen, including the full titration strategy and all clinical criteria, is set out in the structured protocol below.

References

DOI: 10.1093/eurheartj/ehad194

Beta-blockers constitute the first option to reduce arrhythmic burden via a reduction in adrenergic tone, particularly on exercise.
Titration to the maximal tolerated dose has been associated with an improvement in survival from major ventricular arrhythmias in retrospective observational studies.
Beta-blocker therapy is recommended in ARVC patients with VE, NSVT, and VT.
Discontinuation of intense physical exercise has shown a potential to slow the pace of disease progression and reduce the ventricular arrhythmia burden.

View source ↗

What Is the Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy?

References